Foundation Medicine — JP Morgan Healthcare Conference 2018
20 slides from Foundation Medicine's conference presentation, Jan 8, 2018
Slide 1: Personalized Cancer Care. Delivered.
Personalized Cancer Care. Delivered. JP Morgan Healthcare Conference 2018 January 8, 2018 CONFIDENTIAL
Slide 2: Forward Looking Statement
Forward Looking Statement January 8, 2018 This presentation contains forward-looking statements about our business. These statements may be identified by words such as “may,” “will,” “should,” “could,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “forecast
Slide 3: January 8, 2018 CONFIDENTIAL
January 8, 2018 CONFIDENTIAL
Slide 4: 2017: A Year of Transformational Milestones and Accomplishments
Achieved FDA approval and a preliminary National Coverage Determination (NCD) from CMS 2017: A Year of Transformational Milestones and Accomplishments January 8, 2018 Posted record clinical volume Posted record revenue Signed significant new biopharma partnerships, including in the area of Immunothe
Slide 5: The Cancer Care Gap is Enormous
The Cancer Care Gap is Enormous January 8, 2018
Slide 6: The Cancer Care Gap is Enormous: Only 15% get multi-gene testing
The Cancer Care Gap is Enormous January 8, 2018 Only 15% get multi-gene testing
Slide 7: The Cancer Care Gap is Enormous: Another 25% get single biomarker testing
Another 25% get single biomarker testing The Cancer Care Gap is Enormous January 8, 2018
Slide 8: 60% of patients do not receive genomic testing
60% of patients do not receive genomic testing The Cancer Care Gap is Enormous January 8, 2018
Slide 9: Foundation Medicine's Opportunity: Advanced Cancer Patients Deserve Personalized Care
Foundation Medicine’s Opportunity: 10 of 10 All Advanced Cancer Patients Deserve Personalized Care January 8, 2018
Slide 10: FoundationOne CDx: One Test
Foundation Medicine’s Opportunity: 10 of 10 January 8, 2018 CDx TM ONE TEST The FirstFDA Approved broad genomic profiling test with multiple companion diagnostics 4 out of 5Matched to a clinical trial* 35% Matched to a FDA approved therapy* Universal Platform for CDx Development and Access to Target
Slide 11: Landmark Approval: The Path Forward
Landmark Approval: The Path Forward January 8, 2018 90DAYS Comment Period and Administrative Window to Finalize NCDFebruary 28, 2018 FDA Approvaland Preliminary NCDNovember 30, 2017 FDA announces approval, CMS proposes coverage of first breakthrough-designated test to detect extensive number of canc
Slide 12: FoundationOne CDx: Meaningful Medicare Coverage through a National Coverage Determination
50% of FMI’s Solid Tumor Testing*40% Medicare & Medicare Advantage* Ovarian Lung Breast Colorectal Melanoma New FDA approved CDx for additional tumor types Coverage with Evidence Development FoundationOne CDx: Meaningful Medicare Coverage through a National Coverage Determination (NCD) *Estimates ar
Slide 13: FMI: Unique, Synergistic Business
FMI: Unique, Synergistic Business FoundationOne CDx accelerates these synergies PATIENTS CLINICAL Enables access to personalized cancer care BIOPHARMA Provides Efficient, de-risked CDx drug development DATA Expands the largest global database of real-world genomic profiles, fueling better R&D
Slide 14: The Next Chapter of Growth
The Next Chapter of Growth DRIVE CLINICAL ADOPTION AND GLOBAL REACH CONTINUED REIMBURSEMENT PROGRESS EXPAND BIOPHARMAGROWTH 30+PARTNERS BROADEN SUITE OF TARGETED AND IMMUNOTHERAPY OFFERINGS $
Slide 15: January 8, 2018 CONFIDENTIAL
January 8, 2018 CONFIDENTIAL
Slide 16: January 8, 2018 CONFIDENTIAL
January 8, 2018 CONFIDENTIAL
Slide 17: Reimbursement Strategy Removing Barriers for Commercial Payer Expansion
Reimbursement Strategy January 8, 2018 Removing Barriers for Commercial Payer Expansion FDA Approval/ Preliminary NCD from CMS Professional Guidelines Momentum in Personalized Cancer Care Strengthened Commercial Capabilities
Slide 18: Enabling Efficient Drug Development, from Discovery to Commercialization
Enabling Efficient Drug Development, from Discovery to Commercialization January 8, 2018 January 8, 2018 Biopharma Partner of Choice Companion DiagnosticsData Insights: FoundationCORE™ & Flatiron PartnershipMolecular ProfilingSmartTrials™ & Precision EnrollmentCompanion Diagnostics Revenue
Slide 19: Shaping the Targeted and Immunotherapy Landscape with New and Emerging Biomarkers
PD-L1+ TMB-H MSI-H Shaping the Targeted and Immunotherapy Landscape with New and Emerging Biomarkers *Data based on Foundation Medicine experience and Goodman et al, “Tumor Mutational Burden as an independent predictor of response to immunotherapy in diverse cancers.” AACR Aug 29 2017.**FDA website:
Slide 20: Our Mission
Our Mission: 10 of 10
Foundation Medicine — JP Morgan Healthcare Conference 2018 on 6ix